Maurice Zauderer, CEO, Vaccinex discusses pepinemab, the antibody drug being developed by Vaccinex for treatment of Huntington's disease, Alzheimer's disease and lung cancer. Maurice also touches on the relationship between neurodegenerative diseases and cancer, and the commonalities that allow for a treatment like pepinemab to have a potential benefit in both therapeutic areas.
@vaccinex $VCNX #immunotherapy #rarediseases #cancer
Vaccinex.com
Download the transcript here
Empowered Patient Podcast